Fahed, Akl C. http://orcid.org/0000-0002-4849-6389
Philippakis, Anthony A.
Khera, Amit V. http://orcid.org/0000-0001-6535-5839
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (1K08HG010155, 1U01HG011719)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute
Article History
Received: 16 August 2021
Accepted: 9 May 2022
First Online: 25 May 2022
Competing interests
: A.C.F. is a consultant and holds equity in Goodpath. A.A.P. is employed as a Venture Partner at GV, a subsidiary of Alphabet Corporation. A.V.K. is an employee and holds equity in Verve Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; received a sponsored research agreement from IBM Research, and is listed as a co-inventor on a patent application for use of imaging data in assessing body fat distribution and associated cardiometabolic risk.